Press Releases

Indivior Announces Q4 / FY 2021 Financial Results

Slough, UK and Richmond, VA - February 16, 2022 – Indivior PLC (LON: INDV) today announced its financial results for the period ending December 31, 2021. The earnings release, investor presentation and webcast are available at

Download pdf of full press release

Participants may also access the presentation telephonically:

US participants 1-646-741-3167

International participants +44 (0) 2071-928338

Please reference confirmation ID 8268632. A replay of the presentation will be available at

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting


Media Contacts:


Tulchan Communications

+44 207-353-4200

Jason Thompson

Vice President, Investor Relations

Indivior PLC (LON: INDV)

Mobile: 804-402-7123